Two of the most important determinants of cancer outcomes are the culture and behavior of both the provider and the patient, explained Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities.
Two of the most important determinants of cancer outcomes are the culture and behavior of both the provider and the patient, explained Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities.
Transcript (slightly modified)
How do population determinants of risk contribute to disparities in cancer outcomes?
That’s a very important question. By population determinants, I mean those major influencers that affect cancer outcomes. I believe that the 2 most important determinants are culture and behavior. Culture, another word for it might be norms, the traditions by which people have been brought up, and so those norms determine behaviors, and behaviors determine cancer outcomes.
We’ve got to look at it from 2 points of view. One is the provider, and secondly, the patient. From all the research we know that it is the provider who’s the most important influence on the care and quality of the patient’s care, so that if the provider took the initiative to aggressively seek the appropriate care for the individual, more than likely the patient’s going to follow through.
Now from the patient’s perspective, the culture and behavior. When the patient hears about what needs to be done, then it goes through the filter of culture and societal influences, and so I think that’s the extent to which it governs. I can give you some good examples of how both of those influences have worked.
Take for instance the norm of nonsmoking. Nonsmoking now is the norm, and all the societal influences including the environment and including the legislation and restrictions, all favor never smoking or nonsmoking. And so this is an example where an environmental influence can be the, shall we say, the culture that determines the behavior, which is not to smoke or to hopefully never start.
Another example might be, let’s say seatbelts. Seatbelt usage is another kind of a norm that has of course saved lives. So those are some examples of the population determinants.
Now, I focus on tobacco because tobacco is the single most important preventable cause of death, and so that I use as a case of what has worked. The tremendous declines in lung cancer rates are proof that it has worked.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More